A Double-Blind (Sponsor Unblinded), Randomized, Placebo-Controlled, Continuation Single and Repeated Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2838232 With Ritonavir, in Healthy Subjects

Trial Profile

A Double-Blind (Sponsor Unblinded), Randomized, Placebo-Controlled, Continuation Single and Repeated Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2838232 With Ritonavir, in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jan 2017

At a glance

  • Drugs GSK 2838232 (Primary) ; Ritonavir
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 16 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 28 Nov 2016 Status changed from recruiting to active, no longer recruiting.
    • 08 Nov 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top